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ABSTRACT
The timing of lethality caused by homozygosity for a null allele of the epidermal growth factor receptor
(Egfr tm1Mag) in mice is strongly dependent on genetic background. Initial attempts to genetically map back-
ground modifiers using Swiss-derived, outbred CD-1 mice were unsuccessful. To investigate the genetic
architecture contributing to survival of Egfr tm1Mag homozygous embryos, the genetic variability segregating
within the outbred population was partitioned by surveying viability of Egfr tm1Mag mutants using intercrosses
between 129S6/SvEvTAC-Egfr tm1Mag and nine Swiss-derived, inbred strains: ALR/LtJ, ALS/LtJ, APN, APS,
ICR/HaRos, NOD/LtJ, NON/LtJ, SJL/J, and SWR/J. The observations showed that these strains support
varying levels of survival of Egfr tm1Mag homozygous embryos, suggesting that genetic heterogeneity within
the CD-1 stock contributed to the original lack of Egfr tm1Mag modifier detection. Similar to the Swiss-derived
intercrosses, nine congenic strains, derived from 129S6/SvEvTAC, AKR/J, APN, BALB/cJ, BTBR-T tf/tf,
C3H/HeJ, C57BL/6J, DBA/2J, and FVB/NJ inbred backgrounds, also supported varying levels of survival
of Egfr tm1Mag mutants. By intercrossing the congenic lines to create hybrid F1 embryos, different genetic
backgrounds were found to have complementary modifiers. Analysis of the congenic lines argues against
heterosis of outbred backgrounds contributing to Egfr tm1Mag phenotypic variability. A detailed analysis of
the crosses suggests that modifiers function at three distinct stages of development. One class of modifiers
supports survival of Egfr tm1Mag homozygous embryos to mid-gestation, another class supports development
through the mid-gestation transition from yolk-sac to placental-derived nutrient sources, and a third class
supports survival through later stages of gestation. Data from microarray analysis using RNA from wild-
type and Egfr tm1Mag mutant placentas support the existence of extensive genetic heterogeneity and suggest
that it can be molecularly partitioned. This method should be generally useful to partition heterogeneity
contributing to other complex traits.
THE epidermal growth factor receptor (EGFR) is the yama et al. 1991; Shing et al. 1993; Toyoda et al. 1995;prototypical member of a family of related receptor Riese et al. 1996; Strachan et al. 2001). The ligands
tyrosine kinases (RTKs) that includes ERBB2/NEU, encoded by Egf, Tgf, Epgn, and Areg are specific for the
ERBB3, and ERBB4 (Carpenter and Wahl 1990; Gul- EGFR, whereas those encoded by Btc, Ereg, and Dtr are
lick 1998). Activation of the EGFR results in propaga- reported to bind either EGFR or ERBB4 with varying
tion of extracellular signals into the cytoplasm via activa- affinities (Alroy and Yarden 1997; Riese et al. 1998).
tion of signaling cascades. These signals, resulting in When misregulated, most RTKs can contribute to devel-
the alteration of many cellular processes, including pro- opmental disorders and to pathogenesis, such as cancer.
liferation, migration, and differentiation, are initiated Homologous recombination in mouse embryonic
by seven known ligands: epidermal growth factor (EGF), stem (ES) cells was previously used to generate a null
transforming growth factor  (TGF), amphiregulin allele of the Egfr (Threadgill et al. 1995). Phenotypic
(AREG), epiregulin (EREG), betacellulin (BTC), hepa- analysis of mice generated from the targeted ES cells
rin-binding Egf/diphtheria toxin receptor (DTR), and revealed that homozygous Egfr tm1Mag null mutants exhibit
epigen (EPGN; Cohen 1962; Marquardt et al. 1984; peri-implantation to postnatal lethality, depending on
Ciardiello et al. 1991; Elenius et al. 1991; Higashi- the genetic background of the developing embryo. Con-
sequently, the Egfr tm1Mag null allele was the first targeted
mutation to reveal profound variation in survival caused
1Present address: Department of Genetics, CB#7264, University of by differences in genetic background (Sibilia and Wag-
North Carolina, Chapel Hill, NC 27599. ner 1995; Threadgill et al. 1995).
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mutant blastocysts form but then die shortly after im- and the apparent genetic heterogeneity of the modifi-
ers, a detailed analysis of the underlying genetic archi-plantation at 4.5 days post coitus (dpc). These embryos
consist of a loosely arranged inner cell mass with no tecture was performed. Genetic heterogeneity was inves-
tigated using inbred strains of mice, independentlydistinct endoderm. In contrast, on Swiss-derived, out-
bred CD-1 stock, Egfr tm1Mag homozygous pups can survive produced from Swiss-derived, outbred stocks that were
assayed for their ability to modify survival of Egfr tm1Maglonger than 3 weeks post-natally, but are severely runted
and undergo progressive cerebral degeneration and homozygous offspring through intercrosses and back-
crosses with 129S6/SvEvTAC-Egfr tm1Mag heterozygous mice.wasting after birth. Newborn pups, homozygous for the
Egfr tm1Mag mutation, can be distinguished from litter- A series of congenic strains containing the Egfr tm1Mag muta-
tion was also created and the resulting Egfr tm1Mag homozy-mates by waved whiskers and an absence of eyelids, a
phenotype similar to mice homozygous for the hypo- gous mutants were characterized for their stage of lethal-
ity. Furthermore, the congenic strains were intercrossedmorphic Egfr wa2 allele (Luetteke et al. 1994; Fowler
et al. 1995). On an inbred 129S6/SvEvTAC background, to produce hybrid F1 mutants to address the genetic
complexity of the Egfr modifiers. These studies revealedEgfr tm1Mag homozygous embryos die at 11.5 dpc due to a
decreased placental size, compared to littermate con- complex patterns underlying the phenotypic diversity
caused by homozygosity for the Egfr tm1Mag mutation, sug-trols, which is caused by a reduced spongiotrophoblast
layer and disorganization of the labyrinthine tropho- gesting that the numbers and interactions between mod-
ifiers are extensive and function at three distinct stagesblast layer. Surprisingly, on the outbred CD-1 stock, the
Egfr tm1Mag homozygous placentas still exhibit a reduced of placental development. To molecularly validate and
to investigate a method for partitioning genetic hetero-spongiotrophoblast layer; however, there is partial res-
cue of the disorganized labyrinthine trophoblast layer. geneity, gene expression profiling was performed using
microarrays on a subset of placentas. The results revealSeveral causes could contribute to the strain-depen-
dent variation observed with survival of Egfr tm1Mag homo- that placentas from wild-type embryos are similar while
those from different Egfr tm1Mag homozygous embryos mani-zygous mutants, including differences in background
alleles, heterosis, and the maternal uterine environment. fest highly diverse transcriptional differences.
Previous experiments using reciprocal embryo transfers
have eliminated the maternal uterine environment as
MATERIALS AND METHODSa factor contributing to embryo survival (Threadgill et al.
1995). Likewise, tetraploid chimeras were used to defini- Mouse strains and crosses: To generate congenic lines car-
tively demonstrate that variation in embryonic survival is rying the Egfr tm1Mag mutation, donor male mice heterozygous
caused by abnormal placenta development from extra- for the Egfr tm1Mag allele, co-isogenic on the 129S6/SvEvTAC
genetic background, were mated to wild-type female miceembryonic lineages and that embryonic lineages do not
from eight recipient strains. The inbred strains of mice, se-contribute significantly to differential survival of Egfr tm1Mag
lected for their genetic diversity, included AKR/J, APN,homozygous embryos (Sibilia and Wagner 1995). The BALB/cJ, BTBR-T  tf/tf, C3H/HeJ, C57BL/6J, DBA/2J, and
most probable factor contributing to differential survival FVB/NJ. The resulting progeny were backcrossed to their
is the existence of allelic differences between mice that respective recipient strain for at least 10 successive generations
(N10) to generate congenic lines. The backcross progeny werefunction as modifying genes. However, heterosis cannot
genotyped by PCR for presence of the Egfr tm1Mag allele. To de-be discounted since most previous analyses used out-
termine the effect of the Egfr tm1Mag homozygous null mutationbred mice. Conclusive evidence for the existence of on the various genetic backgrounds, heterozygous female and
modifying genes can be obtained only from an analysis male progeny from N10 or greater were intercrossed and em-
of inbred or congenic mouse lines. bryos were collected and analyzed at 10.5, 13.5, or 18.5 dpc.
Embryos were genotyped by PCR and those homozygous forTo address the question of how the same mutation can
the Egfr tm1Mag allele were phenotypically classified for the abilityhave different effects depending on genetic background,
to modify the mid-gestation placental lethality observed ona backcross panel was set up with 129CD1 F1-Egfr tm1Mag het- the donor 129S6/SvEvTAC genetic background. The strains
erozygous mice backcrossed to 129S6/SvEvTAC-Egfr tm1Mag were classified as similar to the original 129S6/SvEvTAC back-
mice to identify genetic modifiers of Egfr tm1Mag. Surviving ground phenotype if the decidua contained either no viable
embryo or residual extra-embryonic membranes at the 13.513.5 dpc N2 generation Egfr tm1Mag homozygous embryos
dpc time point. The strains were classified as rescuing (modi-were subjected to a whole-genome scan to identify CD-1
fying) the mid-gestation lethality if they were phenotypicallyalleles contributing to survival past mid-gestation. Inter- indistinguishable from wild-type or heterozygous littermates
estingly, no statistically significant loci were detected at 10.5 and 13.5 dpc. At 18.5 dpc Egfr tm1Mag homozygous mu-
(D. W. Threadgill, N. J. Schork and T. Magnuson, tants were scored positive for rescue if embryos were alive and
exhibited failure of eyelid closure, smaller size, and reducedunpublished results). However, since CD-1 is an outbred
placenta size characteristic of the Egfr tm1Mag homozygous muta-stock, the inability to localize specific modifiers of the
tion previously described on outbred stocks (Miettinen et al.Egfr tm1Mag phenotype may have been due to the highly
1995; Sibilia and Wagner 1995; Threadgill et al. 1995); homo-
heterogeneous nature of the CD-1 stock. zygosity was confirmed by PCR assay.
To investigate the strong genetic-background-depen- The congenic strains that did not support a robust survival
to term of Egfr tm1Mag homozygous embryos were intercrossed todent phenotypic variation caused by the Egfr tm1Mag allele
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produce hybrid F1 backgrounds to test for genome comple- Microarray hybridization: RNA was reverse transcribed to
cDNA using an anchored oligo(dT) primer, Cy3 or Cy5 dUTP,mentation. The backgrounds tested include 129S6/SvEvTAC,
BALB/cJ, C57BL/6J, and FVB/NJ. Embryos were collected and Superscript II RNaseH RT enzyme (Invitrogen) at 42
for 2 hr. For experimental samples, RNA from wild-type orand genotyped at 13.5 or 18.5 dpc as described above to deter-
mine the ability of the combined genomes to support survival Egfr tm1Mag null placenta was labeled with Cy5 and the placental
reference RNA was labeled with Cy3. Following reverse tran-of Egfr tm1Mag homozygous embryos.
Heterozygous 129S6/SvEvTAC-Egfr tm1Mag mice were also mated scription, the mRNA was degraded by addition of NaOH and
neutralized with HCl. Cy3- and Cy5-labeled cDNA samplesto wild-type mice from nine Swiss-derived, inbred strains,
ALR/LtJ, ALS/LtJ, APN, APS, ICR/HaRos, NOD/LtJ, NON/ were combined, free nucleotides were removed, and the sam-
LtJ, SJL/J, and SWR/J, to generate F1 animals heterozygous ples were concentrated and washed with low TE (10 mm Tris
for the Egfr tm1Mag allele. Heterozygous F1 progeny from within pH 7.5, 0.1 mm EDTA pH 8.0) by filtration through a Micro-
each cross were intercrossed and, only with ALR/LtJ , also back- con-30 filter (Amicon). Samples were collected into an Ep-
crossed to generate segregating F2 and N2 populations, respec- pendorf tube and hybridization buffer was added [300 ng
tively. At 10.5, 13.5, or 18.5 dpc, embryos were analyzed to yeast tRNA, 600 ng poly(A) RNA, 3 SSC, 0.2% SDS]. Microar-
determine the ability of each cross to rescue the mid-gestation ray slides were prehybridized for 45 min in 3 SSC, 0.1%
lethality. The homozygous Egfr tm1Mag F2 embryos were pheno- SDS, 0.2% BSA at 65, washed extensively in ddH2O, dipped
typed as described for the analysis of the congenic strains. in isopropanol, and spun at 500 rpm for 5 min to dry. Heat-
Successful female matings were determined by the presence denatured probe samples were added to 7500-gene mouse
of copulation plugs with the morning of the plugs designated microarrays prepared by the University of North Carolina-
as 0.5 dpc. Pregnant females were euthanized and embryos Chapel Hill Genomics Core and hybridized at 65 for 16–20
were dissected from the uterine horns on the morning of 10.5, hr in humidified hybridization chambers (Telechem); mi-
13.5, or 18.5 dpc into phosphate buffered saline (PBS). In all croarrays were prepared from 60-mer oligo libraries (Compu-
crosses the dam is listed first and the sire second unless other- gen). The microarrays were washed once in 2 SSC/0.1%
wise noted. Mice were fed Purina Mills lab diet 5010 or 5058 SDS for 2 min to remove the coverslips, once in 1 SSC for
and water ad libitum under specific pathogen-free conditions 5 min, and twice in 0.1 SSC for 5 min, all at room tempera-
in an American Association for the Accreditation of Lab Ani- ture with gentle agitation. After centrifugation at 500 rpm for
mal Care approved facility. Mice were euthanized by CO2 5 min at 20 to dry, the microarrays were scanned using a
asphyxiation. GenePix 4000B scanner (Axon Instruments, Foster City, CA).
Genotyping: The placentas and extra-embryonic tissues were A laser detected the individual probes, with the Cy5 probe
separated from the embryo by mechanical dissection and ei- scanning at 635 nm and pseudocolored red and the Cy3 probe
ther whole embryos at 10.5 dpc or pieces of tail from 13.5- detected at 532 nm and pseudocolored green.
and 18.5-dpc embryos were collected for DNA extraction to Microarray data analysis and clustering: GenePix Pro 4.0
determine the genotype of individual embryos. DNAs from (Axon Instruments) was used to locate and grid individual
these samples were isolated by lysing the tissues in 25 mm spots using the image generated by the scanner. After grid-
NaOH/0.2 mm EDTA at 95 for 20 min. The reaction was ding, the raw fluorescent intensities were collected for each
neutralized with an equal volume of 40 mm Tris pH 5.0 and spot and for local background signal. Captured TIFF images
centrifuged at 13,000 rpm for 5 min. A total of 200 ng of corresponding to the two fluorescent labels and the raw inten-
DNA from each lysis reaction was used to genotype embryonic sity measurements were uploaded into a GeneTraffic v2.5
samples by polymerase chain reaction (PCR) with the fol- microarray database (Iobion). The data were normalized us-
lowing primers: Egfr25, 5-GCCCTGCCTTTCCCACCATA-3; ing a subgrid Lowess routine and the local background signals
Egfr26A, 5-AACGTCGTGACTGGGAAAAC-3; and Egfr27, were subtracted (Yang et al. 2002). Hierarchical clusters were
5-ATCAACTTTGGGAGCCACAC-3. PCR conditions were as generated with Euclidean distance to the nearest neighbor
follows: denaturing at 94, primer annealing at 63, and exten- to identify groups of genes with similar expression profiles.
sion at 72 for 40 cycles in a Perkin Elmer (Norwalk, CT) Expression levels across individual samples were represented
9700. PCR products were separated on 1.5% agarose gels; the relative to the median of all samples for each gene.
wild-type Egfr allele yields a 350-bp fragment and the targeted
Egfr tm1Mag allele a 450-bp fragment detected by ethidium bro-
mide staining.
RESULTSStatistical analysis: A one-group chi-square analysis using
StatView (SAS Institute) was carried out for all genetic crosses.
Variable survival of Egfr tm1Mag homozygotes from inter-Collection of placental samples: Timed pregnancies were
crosses with Swiss-derived, inbred strains: Previous whole-collected at 18.5 dpc from Egfr tm1Mag heterozygous ALR129 F1 fe-
males mated to 129S6/SvEvTAC-Egfr tm1Mag heterozygous males. genome scans using intercrosses with Swiss-derived, out-
From each pregnancy, the placenta was dissected from the bred CD-1 mice failed to localize Egfr tm1Mag background
uterus and separated from the embryo, yolk sac, and umbilical modifiers (D. W. Threadgill, N. J. Schork and T.cord in PBS. Placentas were bisected and stored in RNA later
Magnuson, unpublished results). A likely reason that(Ambion, Austin, TX) at 20 or flash frozen in SuperFriendly
Freeze-it (Fisher Scientific) and stored at 80 until RNA was no modifier loci were genetically mapped in the initial
extracted. DNA was extracted from embryonic tissue and the cross is due to genetic heterogeneity of modifiers carried
genotype of each sample was determined by PCR. Total RNA in the outbred CD-1 stocks. A prediction of this hypothe-
was isolated from individual 18.5-dpc placentas using 1–2 ml of
sis is that independent Swiss-derived, inbred strainstrizol (Invitrogen, San Diego) according to the manufacturer’s
should have partitioned out the genetic heterogeneityprotocol. Isolated RNA was quantified using a spectrophotom-
eter and RNA quality analyzed on a Bioanalyzer 2100 (Agilent). and fixed independent and overlapping sets of modifiers
Placental reference RNA was generated by combining 50 g during the inbreeding process. As a consequence, the
of total RNA from eight wild-type 18.5-dpc placentas, three Swiss-derived, inbred strains should show a variable abil-Egfr tm1Mag 18.5-dpc placentas, four wild-type 17.5-dpc placentas,
ity to support embryonic survival of Egfr tm1Mag homozy-two Egfr tm1Mag 17.5-dpc placentas, and one post-natal day (P)
7 and P2 liver. gous mutants.
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TABLE 1
Survival of Egfr tm1Mag homozygous embryos from intercrosses with Swiss-derived, inbred strains
Intercross Age No. of embryos Egfr tm1Mag Viable Egfr tm1Mag No. of
straina (dpc) /:/:/b embryos (%) embryos (%) litters
ICR/HaROS 10.5 30:43:15** 17.0 5.9 7
13.5 25:34:10** 14.5 0.0 9
NON/LtJ 10.5 23:30:23 30.3 18.4 8
13.5 25:28:12** 18.5 3.0 7
18.5 8:11:1* 5.0 0.0 3
NOD/LtJ 10.5 9:31:13 24.5 17.0 5
13.5 24:34:15** 20.5 6.8 7
18.5 15:43:8** 12.1 1.5 8
SJL/J 10.5 10:33:20 32.0 12.7 6
13.5 20:39:10** 14.5 4.3 7
18.5 27:45:19** 20.9 6.6 11
SWR/J 13.5 14:45:21 26.3 21.3 10
18.5 23:47:17 19.5 12.6 10
APS 13.5 17:47:23 26.4 18.4 8
18.5 31:54:16** 15.8 12.9 10
APN 13.5 26:46:16* 18.2 13.6 8
18.5 24:43:11** 14.1 11.5 7
ALS/LtJ 13.5 18:36:17 23.9 18.3 7
18.5 29:71:34* 25.4 14.9 15
ALR/LtJ 13.5 24:46:9** 11.4 10.1 9
18.5 15:44:17 22.4 19.7 6
a All strains were intercrossed with 129S6/SvEvTAC-Egfr tm1Mag.
b P-values: *, 0.05 and **, 0.01 when using a 	2 test for deviation from the expected 25% recovery of
viable Egfr tm1Mag homozygous embryos.
Nine strains, inbred for various phenotypic character- that embryos homozygous for the Egfr tm1Mag null muta-
istics from Swiss-derived, outbred mouse stocks, were tion, co-isogenic on the 129S6/SvEvTAC genetic back-
used to test these predictions; included were ALR/LtJ, ground, are viable and present at expected ratios
ALS/LtJ, APN, APS, ICR/HaRos, NOD/LtJ, NON/LtJ, through 10.5 dpc, but undergo rapid degeneration
SJL/J, and SWR/J (Heston 1963; Crispens 1973; around 11.5 dpc due to severe placental abnormalities
Evans et al. 1974; Casley et al. 1997; Leiter et al. 1998; (Threadgill et al. 1995). Three groups of intercrosses
Graser et al. 1999). Wild-type mice from each inbred were observed. The first group includes crosses with
strain were mated to heterozygous 129S6/SvEvTAC- ICR/HaROS that display poor support for Egfr tm1Mag sur-
Egfr tm1Mag and the resulting F1 progeny were intercrossed. vival at mid-gestation, worse than that on the co-isogenic
The F2 embryos were phenotyped at 10.5, 13.5, and/or 129S6/SvEvTAC genetic background. Interestingly, in-
18.5 dpc (Table 1; Figure 1). Previous analysis showed tercrossing with the ICR/HaRos strain produced only
5.3% viable Egfr tm1Mag homozygous embryos at 10.5 dpc,
with Egfr tm1Mag homozygous embryos being smaller than
either wild-type or heterozygous littermates. The lethal-
ity in ICR;129 intercrosses occurs significantly earlier
than the Egfr tm1Mag phenotype on the co-isogenic 129S6/
SvEvTAC background, suggesting that ICR/HaRos is a
sensitized background, potentially harboring modifiers
that result in decreased viability. Although ICR;129 in-
tercrosses support survival of Egfr tm1Mag homozygous em-
bryos better than non-Swiss-derived, outbred CF-1 stock
does (Threadgill et al. 1995), the ICR/HaROS inbred
strain may nonetheless have modifiers similar to those
in the CF-1 stock.
Crosses with NOD/LtJ, NON/LtJ, and SJL/J repre-
Figure 1.—Survival of Egfr tm1Mag homozygous embryos from sent the second group of intercrosses (Table 1; Figure 1);
intercrosses. All crosses were between 129S6/SvEvTAC-Egfr tm1Mag Egfr tm1Mag homozygous embryos in these crosses showedand a Swiss-derived, inbred strain. Solid bar, high frequency
a variable penetrance in survival past the mid-gestationof survival; dotted bar, intermediate frequency of survival;
dotted line, low frequency of survival. lethality observed on the 129S6/SvEvTAC genetic back-
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ground. Viable NOD;129, NON;129, and SJL;129 F2- phen (Casley et al. 1997). Unlike the other sister strains,
viable Egfr tm1Mag homozygous progeny from APS;129 andEgfr tm1Mag homozygous embryos compose 1.5, 0, and
6.6% of the total embryos at 18.5 dpc, respectively. Al- APN;129 intercrosses are present in approximately equal
frequencies at 18.5 dpc, composing 12.9 and 11.5% ofthough there is a statistically significant reduction in
the number of viable Egfr tm1Mag homozygous embryos at total embryos, respectively. However, the APS;129 and
APN;129 strain combinations, unlike ALR;129 and13.5 dpc, a subset of these appear capable of surviving
until late gestation; the Egfr tm1Mag homozygous embryos ALS;129, show a differential penetrance of surviving
Egfr tm1Mag homozygous mutants at mid-gestation, repre-surviving to late gestation may carry a complete set of
modifying genes from the two parental strains. Interest- senting 18.4 and 13.6%, respectively. Nonetheless, via-
ble Egfr tm1Mag homozygous embryos make up 18.4 andingly, even though NON/LtJ and NOD/LtJ are sister
strains that were derived for a difference in susceptibility 18.3% of the total embryos at 13.5 dpc in the nonsister
strain combinations APS;129 and ALS;129, respectively.to diabetes, with NON/LtJ being a nondiabetic and
NOD/LtJ a diabetic strain (Leiter et al. 1998), the This observation suggests that different Egfr modifiers
from those needed to support development during lateNON;129 mixed genetic background supports less sur-
vival past mid-gestation than NOD;129 does. Only 3% gestation may be necessary to support survival of Egfr tm1Mag
homozygous mutants past mid-gestation.of the embryos collected from NON;129 intercrosses
were viable Egfr tm1Mag homozygous embryos at 13.5 dpc; The final strain analyzed through intercrosses,
SWR/J, was initially derived for an increased susceptibil-no viable Egfr tm1Mag homozygous embryos survived to
18.5 dpc in this cross. The observed difference between ity to tumor formation (Heston 1963). Viable Egfr tm1Mag
homozygous progeny from SWR;129 intercrosses com-the two sister strains suggests that during the process
of inbreeding, NOD/LtJ inherited Egfr tm1Mag modifiers posed 21.3 and 12.6% of all embryos at 13.5 and 18.5
dpc, respectively (Table 1; Figure 1). The SWR/J geneticthat better complement those on the 129S6/SvEvTAC
background to support survival past mid-gestation and background contains modifiers that support robust sur-
vival through mid-gestation, but with reduced survivaleven to term at a low penetrance.
The remainder of the Swiss-derived, inbred strains during late gestation.
Variable survival of Egfrtm1Mag homozygotes from con-compose the third group (Table 1; Figure 1), character-
ized by a robust ability to support survival of Egfr tm1Mag genic strains: Since extended survival of Egfr tm1Mag homo-
zygous mutants is dependent on genetic backgroundhomozygous mutants past the mid-gestation lethality ob-
served on the 129S6/SvEvTAC background. Intercrosses and has been observed only on outbred or mixed back-
grounds generated by intercrosses, the inability to ge-with ALR/LtJ, ALS/LtJ, APN, APS, and SWR/J all sup-
ported viable Egfr tm1Mag homozygous mutants to 18.5 dpc, netically isolate modifiers in crosses using outbred
stocks may also have been due to heterosis of the hybridpreviously observed only on the outbred CD-1 stock.
The ALR;129 intercrosses supported the highest survival backgrounds. To test this possibility, the Egfr tm1Mag muta-
tion was bred onto eight inbred backgrounds, generat-of Egfr tm1Mag homozygous mutants, representing 19.7%
of the total embryos at 18.5 dpc. Likewise, the sister ing a panel of congenic lines and the original co-isogenic
129S6/SvEvTAC strain. The strains were chosen to max-strain to ALR/LtJ, ALS/LtJ, also contains modifiers ca-
pable of supporting survival past mid-gestation, with imize genetic diversity (Beck et al. 2000) and include
129S6/SvEvTAC, AKR/J, APN, BALB/cJ, BTBR-T tf/tf,14.9% of the total embryos being viable Egfr tm1Mag homo-
zygous mutants at 18.5 dpc; ALR/LtJ and ALS/LtJ were C3H/HeJ, C57BL/6J, DBA/2J, and FVB/J.
Although we cannot formally exclude some role forderived for their resistance or sensitivity, respectively,
to alloxan-induced diabetes (Graser et al. 1999). However, heterosis, analysis of the Egfr tm1Mag congenic lines also
revealed three phenotypic groups arguing against heter-in ALR;129 intercrosses, most of the surviving Egfr tm1Mag
homozygous mutants at 18.5 dpc were viable, whereas osis playing a significant role in the survival of Egfr tm1Mag
homozygous mutants. The three groups of strains, simi-nonviable Egfr tm1Mag homozygous progeny compose 10%
of the total embryos from ALS;129 intercrosses. Interest- lar to the groups observed with the intercrosses, include
strains that do not support survival past mid-gestation,ingly, ALS/LtJ is more closely related to NON/LtJ than
to NOD/LtJ on the basis of allelic similarity at microsa- those that show incomplete penetrance of survival past
mid-gestation, and those that show high penetrance oftellite repeat polymorphisms (Graser et al. 1999), and
both ALS/LtJ and NON/LtJ are less able than their mutant survival past mid-gestation (Table 2; Figure 2).
The first group of congenic strains, BALB/cJ, BTBR-Tsister strains to support survival of Egfr tm1Mag homozygous
mutants. This correlation yields additional support for tf/tf, and FVB/NJ, resemble the phenotype previously
described for 129S6/SvEvTAC (Threadgill et al.the segregation of different modifiers from a larger
heterogenous pool present in the founder Swiss-derived 1995), with no viable Egfr tm1Mag homozygous embryos
surviving to 13.5 dpc. Interestingly, homozygosity forpopulations, with some inbred strains supporting func-
tional rescue of the Egfr-dependent placental defect Egfr tm1Mag appears to be even more severe on an FVB/NJ
background than on the 129S6/SvEvTAC background,much better than other strains.
APS and APN represent a third pair of sister inbred with viable FVB/NJ-Egfr tm1Mag mutant embryos compos-
ing only 6.7% of embryos at 10.5 dpc. The FVB/NJstrains derived for differential response to acetamino-
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TABLE 2
Survival of Egfr tm1Mag homozygous embryos from congenic strains
Age No. of embryos Egfr tm1Mag Viable Egfr tm1Mag No. of
Congenic strain (dpc) /:/:/b embryos (%) embryos (%) litters
FVB/NJ 10.5 30:46:13** 14.6 6.7 11
13.5 26:56:7** 7.9 1.1 7
BALB/cJ 10.5 17:27:14* 24.1 17.2 6
13.5 22:26:14** 22.6 0.0 6
BTBR-T  tf/tf 10.5 1:1:1 33.0 33.0 1
13.5 11:19:8** 21.0 0.0 3
18.5 4:18:2** 8.3 0.0 3
129S6/SvEvTAC 10.5 6:12:13 42.0 29.0 4
13.5a ** 0.0
C57BL/6J 10.5 29:20:18 26.9 17.9 10
13.5 19:35:21** 28.0 5.3 10
18.5 17:19:6** 14.3 0.0 7
DBA/2J 10.5 10:14:7 22.6 16.1 5
13.5 17:25:5** 10.6 4.3 6
18.5 22:33:3** 5.2 3.4 9
AKR/J 13.5 27:18:7 13.5 13.5 7
18.5 22:18:6** 13.0 6.5 5
APN 13.5 6:21:5 15.6 12.5 2
18.5 8:11:2 9.5 9.5 2
C3H/HeJ 13.5 4:5:4 31.0 15.4 2
18.5 3:6:3 25.0 8.3 2
a Previously determined that no viable Egfr tm1Mag homozygous embryos are present at 13.5 dpc (Threadgill
et al. 1995).
b P-values: *, 0.05 and **, 0.01 when using a 	2 test for deviation from the expected 25% recovery of
viable Egfr tm1Mag homozygous embryos.
results are reminiscent of Egfr tm1Mag survival observed on gous embryos are detected on the C57BL/6J genetic
the ICR/HaROS intercross or originally reported for background, which may indicate that placentas from
the outbred CF-1 stock (Threadgill et al. 1995). Egfr tm1Mag homozygotes can support fetal development
On C57BL/6J and DBA/2J genetic backgrounds, to mid-gestation with a low penetrance, but is further
representing the second group, viable Egfr tm1Mag homo- compromised at some point later during gestation. In
zygous embryos are recovered at expected ratios at contrast, on a DBA/2J background 3.4% of the embryos
10.5 dpc, but are greatly reduced by 13.5 dpc composing at 18.5 dpc are viable Egfr tm1Mag homozygotes, similar
only 5.3 and 4.3% of the viable embryos at mid-gestation, to the 4.3% frequency observed at mid-gestation. This
respectively. By 18.5 dpc, no viable Egfr tm1Mag homozy- result suggests that although the DBA/2J background
supports survival of Egfr tm1Mag homozygous embryos only
at a low penetrance through mid-gestation, those that
do survive will do so to late gestation.
The third group, composed of AKR/J, APN, and C3H/
HeJ backgrounds, supports relatively robust survival
past mid-gestation, but is less able to support survival
through late gestation. At 18.5 dpc, 6.5, 9.5, and 8.3%
of the embryos are viable Egfr tm1Mag homozygous mutants
on AKR/J, APN, and C3H/HeJ backgrounds, respec-
tively. However, the surviving Egfr tm1Mag homozygous mu-
tants are runted, exhibit failure of eyelid closure, and
have smaller placentas when compared to wild-type lit-
termates.
Despite these differences, occasional Egfr tm1Mag homo-
zygous escapers can be observed. For example, rare
Figure 2.—Survival of Egfr tm1Mag homozygous embryos on Egfr tm1Mag homozygous mutants are born on 129S6/SvEv-congenic backgrounds. Solid bar, high frequency of survival;
TAC and BTBR-T tf/tf backgrounds while a single via-dotted bar, intermediate frequency of survival; dotted line,
low frequency of survival. ble mutant was observed on the FVB/NJ background
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TABLE 3
Survival of Egfr tm1Mag homozygous F1 hybrid embryos
Age No. of embryos Egfr tm1Mag Viable Egfr tm1Mag No. of
Hybrids (dpc) /:/:/a embryos (%) embryos (%) litters
FVB129 F1 13.5 49:71:28** 18.9 8.1 18
18.5 39:69:15** 12.2 8.1 15
BALB129 F1 13.5 17:43:29 32.6 14.6 13
18.5 20:45:14* 17.7 13.9 10
C57129 F1 13.5 22:23:9 16.7 16.7 7
18.5 22:22:11* 20.0 10.9 9
FVBBALB F1 13.5 15:31:20 30.3 12.1 6
18.5 19:29:5** 9.4 3.8 6
C57FVB F1 13.5 8:17:12 32.4 27.0 5
18.5 14:34:4** 7.7 1.9 5
a P-values: *,  0.05 and **,  0.01 when using a 	2 test for deviation from the expected 25% recovery of
viable Egfr tm1Mag homozygous embryos.
at mid-gestation, suggesting that developmental stochas- those from C57FVB F1 are viable at 13.5 dpc, both ge-
nome combinations show a dramatic reduction in survivaltism also contributes to intrastrain variability.
of Egfr tm1Mag homozygous embryos by 18.5 dpc. Thus theGenomic complementation between Egfr tm1Mag congenic
combination of either BALB/cJ or C57BL/6J with thelines: To further support the existence of heteroge-
FVB/NJ genome results in robust survival to mid-gesta-neous groups of modifiers, pairwise F1 hybrid Egfr tm1Mag
tion, but a significant reduction in the number of viablehomozygous embryos were produced by outcrossing the
Egfr tm1Mag homozygous embryos occurs by 18.5 dpc, withcongenic lines incapable of supporting development
only 3.8 and 1.9% viable FVBBALB and C57BALB F1-past mid-gestation (Table 3; Figure 3). While combining
Egfr tm1Mag homozygous embryos, respectively (Table 3).the genomes of inbred lines in F1 hybrids appears to
This indicates that the FVB/NJ genome potentially lacksconfer the ability to support survival past mid-gestation,
or has a reduction in the number or strength of modifi-albeit with variable penetrance, not all combinations of
ers for late gestation. Potentially, the FVB/NJ geneticgenetic backgrounds result in equivalent survival and
background may harbor modifiers that exhibit a nega-none of the hybrid backgrounds support survival past
tive effect on other modifiers of the Egfr tm1Mag homozy-mid-gestation to the level observed in the outbred CD-1
gous phenotype since FVB/NJ, when congenic for thestocks, suggesting that the alleles carried by these strains
Egfr tm1Mag mutation, only partially supports survival toeither are not robust modifiers or are insufficient in
10.5 dpc (Table 2).number to provide complete support for embryonic sur-
Robust, cross-independent recovery of Egfr tm1Mag ho-vival in the absence of Egfr.
mozygous mutants with ALR/LtJ: As an initial step toAlthough neither the FVB/NJ nor BALB/cJ back-
identify modifiers influencing survival of Egfr tm1Mag ho-grounds alone support survival of Egfr tm1Mag homozygous
embryos past 13.5 dpc (Table 2), when either back-
ground is crossed to the 129S6/SvEvTAC background,
embryonic survival is supported at moderate levels past
mid-gestation, with all of these embryos surviving to
term. FVB129 and BALB129 F1-Egfr tm1Mag homozygous
embryos represent 8.1 and 13.9% of the total viable
embryos at 13.5 dpc, respectively, similar to the numbers
surviving at 18.5 dpc (Table 3). Interestingly, all C57129
F1 embryos were viable at 13.5 dpc; however, by 18.5 dpc
viable Egfr tm1Mag homozygous embryos account for only
10.9% of the total embryos (Table 3), a reduction of
50% over the total number of Egfr tm1Mag homozygous
embryos observed.
Viable Egfr tm1Mag homozygous embryos of FVBBALB F1
hybrids account for 12.1% of the total embryos at
13.5 dpc, similar to that observed when either strain is
Figure 3.—Survival of F1 hybrid Egfr tm1Mag homozygous em-crossed to 129S6/SvEvTAC, but unlike the prior crosses, bryos from outcrosses. Solid bar, high frequency of survival;
survival drops to 3.8% at 18.5 dpc. While half of the dotted bar, intermediate frequency of survival; dotted line,
low frequency of survival.FVBBALB F1-Egfr tm1Mag homozygous embryos and all of
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TABLE 4
Survival of Egfr tm1Mag homozygous embryos from ALR/LtJ crosses
Egfr tm1Mag homozygous embryosa
Age Wild-type embryosa No. of
Cross (dpc) (/ and /) Viable Dead Resorbed litters P-value
(ALR129)  129 18.5 186 (76) 26 (10.6) 7 (2.8) 26 (10.6) 19 0.74
129  (ALR129) 18.5 58 (75) 9 (12) 5 (6.5) 5 (6.5) 8 0.95
ALR;129 F2 18.5 59 (77.7) 15 (19.7) 2 (2.6) 0 (0) 6 0.37
a Total number of embryos of each genotype and class. Percentage of total embryos is in parentheses.
mozygous embryos using inbred strains and bypassing two genotypic groups molecularly confirmed the exis-
tence of extensive genetic heterogeneity across individ-the genetic heterogeneity present in outbred stocks,
ALR129 F1-Egfr tm1Mag mice were intercrossed or back- ual placentas and indicates that microarrays will be a
generally useful tool for partitioning genetic heteroge-crossed to 129S6/SvEvTAC-Egfr tm1Mag mice to generate
ALR;129 F2 and N2 progeny, respectively, ostensibly seg- neity contributing to complex traits.
After normalization, 4462 valid probes were retainedregating ALR/LtJ-derived loci contributing to the ro-
bust survival observed with this genetic background (Ta- across all eight hybridizations, revealing interesting
trends after hierarchical clustering of the data frombles 1 and 4). Although only 11% were viable Egfr tm1Mag
homozygous embryos in the backcrosses, roughly half each placenta (Figure 4A). While variation across wild-
type placentas was observed, the extent and levels ofthat observed in the intercrosses, no statistically signifi-
cant reduction in the total number of Egfr tm1Mag homozy- variation are significantly less than that observed across
the Egfr tm1Mag homozygous placentas. The significantgous progeny was observed at 18.5 dpc, with 22–25% of
the recovered embryos being homozygous for Egfr tm1Mag gene expression variation observed across the individual
placenta from Egfr tm1Mag homozygous embryos suggestsin all crosses. The nonviable Egfr tm1Mag homozygous mu-
tants at 18.5 dpc had died within a day or two prior to that not all Egfr tm1Mag homozygous placentas are molecu-
larly similar. This supports the genetic data indicatingcollection. These results suggest that the ALR/LtJ genome
has captured multiple survival modifiers for Egfr tm1Mag that the Egfr tm1Mag modifiers are genetically heteroge-
neous and that survival of Egfr tm1Mag homozygous em-mutants from the genetic heterogeneity originally de-
tected in the outbred CD-1 stocks. These alleles need bryos is due to differential segregation of a heteroge-
neous group of modifying genes. Even with these limitedto be partitioned further via subsequent backcrossing
or alternative approaches to efficiently identify individ- data, it appears that there are at least two major classes
of Egfr tm1Mag homozygous placentas at 18.5 dpc: thoseual or groups of modifiers capable of altering survival
of Egfr tm1Mag homozygous mutants. that are more similar to the wild-type placental gene
profile (Figure 4A, samples 4–5) and those that showMolecular heterogeneity of Egfr tm1Mag modifiers revealed
by microarray analysis: Microarray technology, widely more divergence in gene expression (Figure 4A, sam-
ples 6–8).used to distinguish tumor classes on the basis of global
similarities to steady-state differences in cellular tran- The eight hybridizations were further analyzed by
sampling only those genes with a twofold or greaterscript levels (DeRisi et al. 1996; Perou et al. 1999; Rick-
man et al. 2001), was used to investigate the genetic change in gene expression across all valid spots, result-
ing in 141 genes meeting the more stringent criteriaheterogeneity associated with the number and intensity
of modifying alleles segregating in the ALR;129 crosses. (Figure 4B). Similar to the entire data set, the 141 genes
in the three wild-type samples were generally more simi-For the microarrays, total placental RNA was extracted
from viable 18.5 dpc wild-type and Egfr tm1Mag homozygous lar in expression than those in the five Egfr tm1Mag homo-
zygous placentas with greater heterogeneity notedembryos and compared to a common reference RNA.
The placental samples were obtained from N2 embryos, across the Egfr tm1Mag homozygous samples. Gender of the
embryos did not influence the clustering results (dataproduced by backcrossing ALR129 F1-Egfr tm1Mag females
to 129S6/SvEvTAC-Egfr tm1Mag males such that individual not shown). Likewise, littermates did not cluster to-
gether, suggesting that the observed molecular profilessamples would be segregating heterogeneous ALR/LtJ-
derived alleles capable of modifying survival of Egfr tm1Mag are dependent on the alleles carried by the individual
placental samples.homozygous embryos.
Gene expression profiles using placental RNA from
five individual Egfr tm1Mag homozygous and three wild-
DISCUSSION
type matched littermate controls were analyzed to reveal
numerous differentially expressed genes between wild- The placenta is a highly specialized yet transitory or-
gan necessary for nutrient and waste exchange betweentype and Egfr tm1Mag homozygous placentas (Figure 4).
Furthermore, the level of individual variation across the the mother and the developing fetus in mammals and
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Figure 4.—Clustering of placental samples us-
ing transcriptional data obtained from micro-
arrays. All samples were from 18.5 dpc placentas.
(A) One-dimensional clustering of placental sam-
ples using 4462 genes differentially expressed
among samples. (B) One-dimensional clustering
of placental samples using the 141 genes with a two-
fold or greater difference in gene expression among
samples. Brackets represent relative similarity in
overall transcriptional profiles with more related
samples appearing closer together and with shorter
brackets. Samples 1–3 and 4–8 represent placentas
collected from Egfr wild-type and Egfr tm1Mag homozy-
gous mutant embryos, respectively.
is composed of multiple cell types, including mesenchy- C3H/HeJ, C57BL/6J, DBA/2J, and FVB/NJ, devel-
oped into congenics. Most of the Swiss-derived strainsmal cells, endothelial cells of the labyrinthine vasculara-
ture, hormone-secreting and glycogen cells of the spon- have the ability, at least partially, to support survival of
Egfr tm1Mag homozygous mutants through mid-gestation,giotrophoblast, and trophoblast giant cells. Given the
diverse roles of the various cell types in the placenta, while more distantly related strains, like AKR/J, APN,
and C3H/HeJ, and to a lesser extent DBA/2J, also havevariability in lethality of Egfr tm1Mag homozygous mutants
may be caused by functional differences in hormone this ability. Although many Swiss-derived strains modify
the mid-gestation lethality similarly, the data in theirproduction, cytokine signaling, transcription factors,
cell cycle regulation, and growth factor signaling in one entirety suggest that there are differential effects of
modifying genes segregating among the various geneticor more cell types.
One possible mechanism to explain the variable phe- backgrounds (Table 5). Our data also suggest that EGFR
is required at three distinct stages of development: priornotypes observed with Egfr tm1Mag homozygous embryos is
heterosis. However, the current results do not support to mid-gestation, at mid-gestation, and during late gesta-
tion (Figure 5). Various combinations of overlappingthis mechanism as heterosis cannot explain the reduced
survival of Egfr tm1Mag homozygous embryos from NON;129 or independent modifiers likely act at critical stages
throughout gestation and contribute to the genetic het-and ICR;129 intercrosses. If heterosis were to account
for the ability to rescue the mid-gestation lethality and erogeneity observed in previous attempts to map mod-
ifiers of the Egfr tm1Mag homozygous phenotype.the inability to genetically map specific modifiers, one
would expect a uniform rescue across various hybrid The ICR/HaRos and FVB/NJ backgrounds resemble
the outbred CF-1 background in that the embryo isbackgrounds, which was not observed in this study. Fur-
thermore, since Egfr tm1Mag homozygous embryos can sur- already compromised prior to the switch from yolk sac
to the placental-mediated nutrient exchange that occursvive, albeit at a low penetrance, to birth on the inbred
AKR/J, APN, C3H/HeJ, and DBA/2J genetic back- at mid-gestation. The FVB/NJ strain, a Swiss-derived
strain, appears to exhibit the same inability to supportgrounds (Table 2), homozygosity is sufficient to support
survival providing the optimal combination of alleles is Egfr tm1Mag homozygous embryo survival that is observed
with ICR;129 intercrosses, but not as severely as the non-present. Likewise, the Egfr tm1Mag null mutation on a non-
Swiss-derived, outbred CF-1 background is peri-implan- Swiss-derived, outbred CF-1. This indicates that the first
critical window for the EGFR activity during develop-tation lethal at e4.5, which is earlier than would be
expected if heterosis was responsible for the genetic ment occurs prior to 10.5 dpc. Since, the Egfr tm1Mag muta-
tion on FVB/NJ and ICR/HaRos backgrounds cannotvariation observed.
A much more likely explanation for Egfr tm1Mag pheno- support survival to mid-gestation, they either lack spe-
cific modifying alleles or have strong suppressor alleles.typic variability is through the action of modifier genes.
Two groups of strains were used in this study to investi- Furthermore, of the parental strains not supporting sur-
vival past mid-gestation, the BALB.129 and FVB.129 F1gate the genetic architecture of Egfr tm1Mag modifiers: the
Swiss-derived strains, ALR/LtJ, ALS/LtJ, APN, APS, hybrids most effectively rescue the placental mid-gesta-
tion lethality. However, combinations of FVB/NJ andICR/HaRos, NON/LtJ, NOD/LtJ, SWR/J, and SJL/J,
in intercrosses and a panel of genetically diverse strains, BALB/cJ show a reduced ability to rescue the mid-gesta-
tion lethality. These observations suggest that the FVB/NJ129S6/SvEvTAC, AKR/J, APN, BALB/cJ, BTBR-T tf/tf,
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TABLE 5
Predicted classes of modifiers present in different inbred strains
Presence of modifiersb
Prior to mid-gestation Mid-gestation After mid-gestation
Strain Groupa (4.5–9.5 dpc) (10.5–13.5 dpc) (14.5–18.5 dpc)
FVB/NJ 1 N N NDc
ICR/HaROS 1 N N ND
129S6/SvEvTAC 2 Y N ND
BALB/cJ 2 Y N ND
BTBR-T  tf/tf 2 Y N ND
NON/LtJ 2 Y N N
NOD/LtJ 2 Y N N
C57BL/6J 2 Y Y/N N
SJL/J 2 Y Y/N Y
DBA/2J 2 Y Y/N Y
AKR/J 3 Y Y Y/N
C3H/HeJ 3 Y Y Y/N
SWR/J 3 Y Y Y/N
ALR/LtJ 3 Y Y Y
ALS/LtJ 3 Y Y Y
APN 3 Y Y Y
APS 3 Y Y Y
a Category of strains based upon level of support for survival of Egfr tm1Mag homozygous mutants.
b Predicted class modifiers that are present (Y), absent (N), or weakly present (Y/N) from each strain.
c ND, cannot determine since embryos did not survive long enough.
and BALB/cJ genetic backgrounds contain similar over- embryos at 13.5 dpc. Given the robust and highly hetero-
geneous composition of Egfr tm1Mag homozygous modifi-lapping and noncomplementing alleles modifying mid-
gestation survival. ers in Swiss-derived, outbred mice, it is not surprising
that during the process of inbreeding, most strains cap-The second critical window for EGFR activity occurs
at mid-gestation when the placenta replaces the yolk sac tured alleles that support survival of Egfr tm1Mag homozy-
gous embryos at some level through mid-gestation. Theas the primary mediator of nutrient and waste exchange.
Most of the strains tested are able to survive, at least with alleles involved in modifying the Egfr tm1Mag homozygous
phenotype appear to be numerous and since they alsoreduced penetrance, past mid-gestation. Combinations
among ALR/LtJ, ALS/LtJ, APN, and APS and 129S6/ confer an increase in fecundity via increases in viability,
they may have been inadvertently selected for duringSvEvTAC as well as AKR/J, APN, and C3H/HeJ and, to
a lesser extent, C57BL/6J, DBA/2J, NOD/LtJ, SJL/J, the derivation of the Swiss-derived, inbred strains.
The third window for activity of Egfr tm1Mag modifiersand SWR/J, all support viable Egfr tm1Mag homozygous
Figure 5.—Schematic of embryonic
lethality of Egfr tm1Mag homozygous mu-
tants. The time line depicts when the
majority of Egfr tm1Mag homozygous em-
bryos on specific strains are affected by
modifying alleles. Group 1 strains pri-
marily die prior to mid-gestation, group
2 at mid-gestation, and group 3 during
late gestation.
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occurs between 13.5 and 18.5 dpc of gestation. For influenced by, the segregation of genes that modify the
Egfr tm1Mag placental phenotype.ALR;129, ALS;129, APS;129, APN;129, and SJL;129 in-
tercross progeny homozygous for Egfr tm1Mag as well as the The role of EGFR during placental development is
proving to be complex, and the EGFR-deficient pheno-congenic APN and DBA/2J strains, it appears that if
the embryos can live past 13.5 dpc, then they will survive type has the potential for being modified by many genes.
Since the phenotypic consequences of Egfr tm1Mag pheno-to term. The comparable numbers of viable embryos
observed at 13.5 and 18.5 dpc for each of these strains type modification can be attributed to many genes segre-
gating within individual animals, their detection has re-compared to strains with similar survival at 13.5 dpc
but with dramatically reduced survival at 18.5 dpc, like mained elusive. Furthermore, the variation in the
Egfr tm1Mag homozygous phenotypes may be attributed toAKR/J, C3H/HeJ, and SWR;129 intercrosses, further
support the hypothesis for a third critical window during the presence of many interchangeable modifier variants
with strong effects or to larger groups of genes, withdevelopment when the EGFR is needed.
Currently the dissection of complex traits has moved each gene having only a small effect on the Egfr tm1Mag
phenotype. When all of these genes are combined in theto the forefront of genetics with many disease processes
being controlled or influenced by complex genetic in- appropriate context, the resulting genetic complement
has a synergistic effect on the Egfr tm1Mag homozygousteractions. The experiments with Egfr tm1Mag homozygous
phenotypes are complicated by the fact that the quanti- phenotype. The genetic studies presented here support
the existence of multiple genes of varying strength thattative variable is the time of embryonic survival. Conse-
quently, this trait requires the use of alternative methods can modify the Egfr tm1Mag homozygous phenotype.
The current results also have significant implicationsfor identifying the modifier genes. Microarray technol-
ogy is one method that has been used frequently to par- for various disease states. For example, aberrant EGFR
signaling has been implicated in intrauterine growthtition genetic heterogeneity using the relative change
in gene expression between samples (Jansen and Nap retardation (IUGR) and in cancer (Dassonville et al.
1993; Rusch et al. 1993; Fondacci et al. 1994; Grandis2001; Wayne and McIntyre 2002). The advantage of
microarrays is that the technique enables large-scale et al. 1998; Tewari et al. 2000; Umekita et al. 2000).
EGFR inhibitors are currently being widely tested toanalysis of many genes concurrently, thus giving a global
view of the relationship between samples or individuals treat many forms of cancer and the early results have
been mixed (Arteaga and Baselga 2003; Grunwaldat the molecular level. In the case of the Egfr locus, the
use of microarrays may allow for the identification of and Hidalgo 2003; Mendelsohn and Baselga 2003).
Modifying genes that compensate for EGFR loss in thesubclasses of mutants that possess similar or identical
sets of modifiers that segregate in an otherwise heteroge- Egfr tm1Mag homozygous mutants may also contribute to
resistance to anti-EGFR therapy. Consequently, it is prob-neous background. Analysis of many samples may per-
mit the partitioning of the Egfr tm1Mag homozygous survi- able that EGFR inhibitors currently being evaluated in
human clinical trials will have highly variable rates ofvors into distinct molecular classes; these individual
classes can then be potentially linked through classical success that are determined by an individual patient’s
genetic background and the EGFR modifying alleles thatquantitative trait analysis to specific genomic regions mod-
ifying the placental phenotype. Preliminary analysis of they harbor. Similarly, the Egfr tm1Mag-modifying genes
present in mouse strains may provide useful diagnosticfive Egfr tm1Mag homozygous placentas shows variation in
gene expression across individual placentas, consistent markers and therapeutic targets to treat IUGR and to
identify patients that will respond to anti-EGFR therapy.with a heterogeneous modification at the molecular level.
There are limits to the information that can be mined We thank W. L. Casley (Health Canada) for providing the APS and
from gene expression profiling. DNA microarrays esti- APN strains and R. W. Elliott (Roswell Park Cancer Institute) for pro-
viding the ICR/HaROS strain. Thanks go to members of our lab formate only the relative levels of transcription between
helpful suggestions during preparation of the manuscript. This worktwo samples, but within the cell there are many other
was supported by National Institutes of Health grant HD39896 andlevels of regulation that are being carried out, such as
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